Zosano Pharma (NASDAQ:ZSAN) Upgraded at Zacks Investment Research
Zosano Pharma (NASDAQ:ZSAN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Saturday, Zacks.com reports. The firm currently has a $1.00 target price on the biotechnology company’s stock. Zacks Investment Research‘s target price would suggest a potential upside of 17.19% from the stock’s previous close.
According to Zacks, “Zosano Pharma Corporation is a biopharmaceutical company. It is engaged in developing a transdermal micro needle patch system to deliver formulations of existing drugs through the skin for the treatment of a variety of indications. The Company’s lead product candidates include Weekly ZP-PTH for severe osteoporosis; ZP-Glucagon for severe hypoglycemia and ZP-Triptan, for migraine. Zosano Pharma Corporation is headquartered in Fremont, California. “
A number of other equities research analysts have also commented on the company. ValuEngine upgraded Zosano Pharma from a “hold” rating to a “buy” rating in a research report on Thursday, April 2nd. BTIG Research decreased their price objective on Zosano Pharma from $16.00 to $7.00 and set a “buy” rating for the company in a research report on Friday, March 27th. HC Wainwright reaffirmed a “buy” rating and set a $4.00 price target on shares of Zosano Pharma in a research note on Friday, May 15th. Finally, Maxim Group reaffirmed a “buy” rating on shares of Zosano Pharma in a research note on Wednesday. Six analysts have rated the stock with a buy rating, Zosano Pharma currently has an average rating of “Buy” and a consensus price target of $4.00.
Zosano Pharma (NASDAQ:ZSAN) last announced its quarterly earnings data on Thursday, May 14th. The biotechnology company reported ($0.24) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.28) by $0.04. As a group, sell-side analysts expect that Zosano Pharma will post -0.5 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Sabby Management LLC purchased a new stake in shares of Zosano Pharma during the 1st quarter worth about $114,000. Telemetry Investments L.L.C. raised its stake in shares of Zosano Pharma by 202.7% in the 1st quarter. Telemetry Investments L.L.C. now owns 2,607,767 shares of the biotechnology company’s stock valued at $1,466,000 after acquiring an additional 1,746,267 shares in the last quarter. BlackRock Inc. raised its stake in shares of Zosano Pharma by 6.8% in the 1st quarter. BlackRock Inc. now owns 385,675 shares of the biotechnology company’s stock valued at $216,000 after acquiring an additional 24,431 shares in the last quarter. UBS Group AG raised its stake in shares of Zosano Pharma by 45.8% in the 1st quarter. UBS Group AG now owns 99,932 shares of the biotechnology company’s stock valued at $56,000 after acquiring an additional 31,375 shares in the last quarter. Finally, Banco Bilbao Vizcaya Argentaria S.A. bought a new position in shares of Zosano Pharma in the 4th quarter valued at approximately $182,000. 12.45% of the stock is owned by institutional investors.
Zosano Pharma Company Profile
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its lead product candidate is M207, a proprietary formulation of zolmitriptan used for the treatment of migraine.
Featured Story: What is the Federal Reserve?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zosano Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma and related companies with MarketBeat.com's FREE daily email newsletter.